inclusion criteria: 1. signed patient information sheet and informed consent form to participate in the study. 2. men and women aged 18 years and older. 3. patients hospitalized with a diagnosis of covid-19. 4. the diagnosis of covid-19 was confirmed by positive reverse transcription polymerase chain reaction (rt-pcr) test for sars-cov-2, performed no earlier than 7 days before hospitalization or at screening. 5. moderate severity of covid-19 with pneumonia with at least 1 of the following symptoms: * fever above 38 °c; * cough; * shortness of breath during physical exertion; * c reactive protein (crp) of blood serum \> 10 mg/l; * spo2 \< 95% 6. the capability of oral drug administration. 7. the patients' consent to use adequate contraception methods during the study (condom with spermicide) and for 3 months following completion.

inclusion criteria: 1. signed patient information sheet and informed consent form to participate in the study. 2. men and women aged 18 years and older. 3. patients hospitalized with a diagnosis of covid-19. 4. the diagnosis of covid-19 was confirmed by positive reverse transcription polymerase chain reaction (rt-pcr) test for sars-cov-2, performed no earlier than 7 days before hospitalization or at screening. 5. moderate severity of covid-19 with pneumonia with at least 1 of the following symptoms: * fever above 38 °c; * cough; * shortness of breath during physical exertion; * c reactive protein (crp) of blood serum \> 10 mg/l; * spo2 \< 95% 6. the capability of oral drug administration. 7. the patients' consent to use adequate contraception methods during the study (condom with spermicide) and for 3 months following completion.

inclusion criteria: signed patient information sheet and informed consent form to participate in the study. men and women aged 18 years and older. patients hospitalized with a diagnosis of covid-19. the diagnosis of covid-19 was confirmed by positive reverse transcription polymerase chain reaction (rt-pcr) test for sars-cov-2, performed no earlier than 7 days before hospitalization or at screening. moderate severity of covid-19 with pneumonia with at least 1 of the following symptoms: fever above 38 °c; cough; shortness of breath during physical exertion; c reactive protein (crp) of blood serum > 10 mg/l; spo2 < 95% the capability of oral drug administration. the patients' consent to use adequate contraception methods during the study (condom with spermicide) and for 3 months following completion.

inclusion criteria: signed patient information sheet and informed consent form to participate in the study. men and women aged 18 years and older. patients hospitalized with a diagnosis of covid-19. the diagnosis of covid-19 was confirmed by positive reverse transcription polymerase chain reaction (rt-pcr) test for sars-cov-2, performed no earlier than 7 days before hospitalization or at screening. moderate severity of covid-19 with pneumonia with at least 1 of the following symptoms: fever above 38 °c; cough; shortness of breath during physical exertion; c reactive protein (crp) of blood serum > 10 mg/l; spo2 < 95% the capability of oral drug administration. the patients' consent to use adequate contraception methods during the study (condom with spermicide) and for 3 months following completion.

inclusion criteria: 1. signed patient information sheet and informed consent form to participate in the study. 2. men and women aged 18 years and older. 3. patients hospitalized with a diagnosis of covid-19. 4. the diagnosis of covid-19 was confirmed by positive reverse transcription polymerase chain reaction (rt-pcr) test for sars-cov-2, performed no earlier than 7 days before hospitalization or at screening. 5. moderate severity of covid-19 with pneumonia with at least 1 of the following symptoms: - fever above 38 °c; - cough; - shortness of breath during physical exertion; - c reactive protein (crp) of blood serum > 10 mg/l; - spo2 < 95% 6. the capability of oral drug administration. 7. the patients' consent to use adequate contraception methods during the study (condom with spermicide) and for 3 months following completion.

inclusion criteria: 1. signed patient information sheet and informed consent form to participate in the study. 2. men and women aged 18 years and older. 3. patients hospitalized with a diagnosis of covid-19. 4. the diagnosis of covid-19 was confirmed by positive reverse transcription polymerase chain reaction (rt-pcr) test for sars-cov-2, performed no earlier than 7 days before hospitalization or at screening. 5. moderate severity of covid-19 with pneumonia with at least 1 of the following symptoms: - fever above 38 °c; - cough; - shortness of breath during physical exertion; - c reactive protein (crp) of blood serum > 10 mg/l; - spo2 < 95% 6. the capability of oral drug administration. 7. the patients' consent to use adequate contraception methods during the study (condom with spermicide) and for 3 months following completion.